Insulin analogues

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 2, 2001, Pages 95-100

  Buse, J B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO;

DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW;

EID: 0035103630     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200104000-00007     Document Type: Review

References (17)

1. Insulin analogues and their potential in the management of diabetes mellitus
2. Genetically engineered insulin analogs: Diabetes in the new millenium
3. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime
4. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c
5. Metabolic and immunologic effects of insulin lispro in gestational diabetes
6. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
7. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in type 1 diabetes
8. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes
9. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus
10. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin
11. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
12. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
13. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
14. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
15. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
16. Insulin glargine